Cargando…

Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study

Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia (CML) to maximise treatment effectiveness. The main objective is to measure adherence to IM by evaluating individual patient characteristics, personal behaviour and, treatment related psychological factors in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapoor, Jyotsna, Agrawal, Narendra, Ahmed, Rayaz, Sharma, Sanjeev Kumar, Gupta, Anshul, Bhurani, Dinesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344173/ https://www.ncbi.nlm.nih.gov/pubmed/25745540 http://dx.doi.org/10.4084/MJHID.2015.013

Ejemplares similares

A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience
por: Singh, Reema, et al.
Publicado: (2021)

Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India
por: Mehta, Pallavi, et al.
Publicado: (2021)

Study of clinical characteristics, risk factors and outcomes for tuberculosis post allogeneic stem cell transplant: never count it out
por: Kapoor, Jyotsna, et al.
Publicado: (2021)

Hemophagocytic Lymphohistiocytosis (HLH): A Rare Cause of Primary Engraftment Failure Post Autologous Stem Cell Transplant
por: Mehta, Pallavi, et al.
Publicado: (2023)

Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
por: Philip, Chepsy C, et al.
Publicado: (2022)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients
por: Chhikara, S, et al.
Publicado: (2017)

Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female
por: Agrawal, Prabhat, et al.
Publicado: (2015)

Outcomes of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: Multicenter Retrospective Analysis
por: Agrawal, Narendra, et al.
Publicado: (2021)

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
por: Scerni, Ana Carolina Costa, et al.
Publicado: (2009)

Clinical and Epidemiological Profile of Elderly Hodgkin’s Lymphoma in India
por: Sharma, Manish, et al.
Publicado: (2022)

Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience
por: Swain, Trupti Rekha, et al.
Publicado: (2022)

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies
por: Jeyaraman, Preethi, et al.
Publicado: (2021)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
por: Kumar, Rahul, et al.
Publicado: (2020)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
por: Moshfeghi, Kamran, et al.
Publicado: (2013)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Chronic myeloid leukemia in the Imatinib era – Compilation of Indian data from 22 centers involving 8115 patients
por: Parikh, Purvish, et al.
Publicado: (2013)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
por: Al-Dewik, Nader I., et al.
Publicado: (2016)

Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon
por: Andrade, Alan Rodrigues, et al.
Publicado: (2019)

End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL-may be the way forward
por: Patra, Pritish Chandra, et al.
Publicado: (2023)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
por: Chen, Li-Chia, et al.
Publicado: (2013)

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
por: Estrada, Natalia, et al.
Publicado: (2021)

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
por: dos Reis, Samuel Roosevelt Campos, et al.
Publicado: (2013)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
por: Chen, Teng-Chou, et al.
Publicado: (2013)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_k4srkh2i2t06as9kvgb9tlf58a